After FDA no, MSD/Daiichi post new data with lung cancer ADC
The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC) was turned down by the FDA in June as a third-line or later treatment for locally advanced or metastatic EGFR-mutated NSCLC because of problems at a third-party manufacturer.
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer (NSCLC),
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival compared to chemotherapy.
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.
The Pharma Letter1d
Patritumab deruxtecan closer to market
The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC patients who received prior EGFR ...
precisionmedicineonline2d
Merck, Daiichi Sankyo to Discuss Antibody-Drug Conjugate Data in EFGR-Mutated NSCLC With Regulators
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
GlobalData on MSN1d
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...
BioSpace2d
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
FierceBiotech2d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
PipelineReview.com4d
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
TOKYO, Japan & BASKING RIDGE, NJ, USA I 13, 2024 I Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab ...